Acurx Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Director Carl Sailer was granted 2,150 stock options as part of the Acurx Pharmaceuticals director compensation policy.
NASDAQ
Director Jack H. Dean was granted 2,150 stock options as part of the Acurx Pharmaceuticals director compensation policy.
NASDAQ
Acurx Pharmaceuticals director James J. Donohue was granted 2,150 stock options as part of the company's director compensation policy.
NASDAQ
Director Thomas L. Harrison was granted 2,150 stock options as part of the company's director compensation policy.
NASDAQ
Director Joseph C. Scodari was granted 2,150 stock options as part of the Acurx Pharmaceuticals director compensation policy.
NASDAQ
Director Robert J. DeLuccia was granted 37,100 stock options in Acurx Pharmaceuticals, Inc. as part of a compensation plan.
NASDAQ
Acurx Pharmaceuticals CEO David P. Luci was granted 37,100 stock options as part of an equity compensation package.
NASDAQ
Acurx Pharmaceuticals, Inc. reports the grant of stock options to Chief Financial Officer Robert G. Shawah.
NASDAQ
Robert G. Shawah, CFO of Acurx Pharmaceuticals, was granted stock options to purchase 145,500 shares of the company's common stock on February 5, 2025.
NASDAQ
Acurx Pharmaceuticals' CEO, David P. Luci, was granted stock options to purchase 250,000 shares of the company's common stock on February 5, 2025.
NASDAQ
Robert DeLuccia, a director of Acurx Pharmaceuticals, was granted stock options to purchase 250,000 shares of the company's common stock on February 5, 2025.
NASDAQ
Joseph C. Scodari, a director of Acurx Pharmaceuticals, acquired 24,631 shares of common stock and warrants in a registered direct offering and concurrent private placement.
NASDAQ
Director Carl Sailer reports acquisition of Acurx Pharmaceuticals common stock and warrants through a registered direct offering and concurrent private placement.
NASDAQ
David P. Luci, CEO of Acurx Pharmaceuticals, purchased 49,261 shares of common stock and warrants in a registered direct offering and concurrent private placement.
NASDAQ
Form 4: Acurx Pharmaceuticals Director James J. Donohue Acquires Shares and Warrants in Direct Offering
Director James J. Donohue increased his holdings in Acurx Pharmaceuticals through a direct stock offering and private placement of warrants.
NASDAQ
Robert J. DeLuccia, a director at Acurx Pharmaceuticals, purchased shares and warrants in a registered direct offering and concurrent private placement.
NASDAQ
Director Jack H. Dean acquired shares and warrants of Acurx Pharmaceuticals through a registered direct offering and concurrent private placement.
NASDAQ
Director Joseph C. Scodari acquired 12,000 stock options in Acurx Pharmaceuticals on June 17, 2024, related to his board service.
NASDAQ
Director Carl Sailer acquired 12,000 stock options in Acurx Pharmaceuticals on June 17, 2024, related to his board service.
NASDAQ
Director Thomas Harrison acquired 12,000 stock options in Acurx Pharmaceuticals on June 17, 2024, related to his board service.
NASDAQ
Director James J. Donohue acquired 12,000 stock options in Acurx Pharmaceuticals on June 17, 2024, related to his board service.
NASDAQ
Director Jack H. Dean acquired 12,000 stock options in Acurx Pharmaceuticals on June 17, 2024, related to his board service.
NASDAQ
David P. Luci, CEO of Acurx Pharmaceuticals, was granted stock options to purchase 250,000 shares of the company's common stock on February 23, 2024.
NASDAQ
Robert G. Shawah, CFO of Acurx Pharmaceuticals, was granted stock options to purchase 145,000 shares of the company's common stock on February 23, 2024.
NASDAQ
Robert J. DeLuccia, a director and 10% owner of Acurx Pharmaceuticals, was granted stock options to purchase 250,000 shares of the company's common stock on February 23, 2024.